KM Research Hub
← 返回论文库
部分完成 入排:符合 图源:可得 入排置信度 0.98

Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial.

Elizabeth A Mittendorf, Zoe June Assaf, Nadia Harbeck, Hong Zhang, Shigehira Saji, Kyung Hae Jung, Roberto Hegg, Andreas Koehler, Joohyuk Sohn, Hiroji Iwata, Melinda L Telli, Cristiano Ferrario, Kevin Punie, Aditi Qamra, Max Dieterich, Yun Xu, Mario Liste-Hermoso, Esther Shearer-Kang, Luciana Molinero, Stephen Y Chui, Carlos H Barrios

Nat Med 31(7) 2397-2404

PMID40467898
PMCIDPMC12283416
DOI10.1038/s41591-025-03725-4
发表日期2025-06-04
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

Previously published results demonstrated that the randomized phase 3 IMpassion031 trial met its primary objective: adding atezolizumab to neoadjuvant chemotherapy significantly improved pathologic complete response (pCR) rate in patients with stage II/III triple-negative breast cancer (TNBC). Here we report the prespecified final analysis of the secondary endpoints with 3 years' follow-up, together with exploratory analyses of circulating tumor (ct)DNA. Patients with previously untreated stage II/III TNBC enrolled in 75 academic and community sites in 13 countries were randomized 1:1 to receive neoadjuvant chemotherapy with either peri-operative atezolizumab (n = 165) or preoperative placebo (n = 168). Descriptive secondary endpoints included event-free, disease-free and overall survival. Long-term outcomes favored the atezolizumab group (event-free survival hazard ratio (HR), 0.76; 95% confidence interval (CI), 0.47-1.21; disease-free survival HR, 0.76; 95% CI, 0.44-1.30; overall survival HR, 0.56; 95% CI, 0.30-1.04). Among patients without pCR, 14 of 70 (20%) atezolizumab-treated and 33 of 99 (33%) placebo-treated patients received additional adjuvant therapy, frequently capecitabine. In exploratory biomarker analyses, patients with baseline ctDNA-negative status (6%) had excellent long-term outcomes. Most patients (87%) had cleared ctDNA at surgery. ctDNA-positive status at surgery identified a subset of non-pCR patients with poorest prognosis. Long-term safety was consistent with primary results. These data show that adding atezolizumab to chemotherapy for stage II/III TNBC is associated with favorable long-term outcomes, and ctDNA dynamics provide prognostic value beyond pCR. ClinicalTrials.gov identifier: NCT03197935 .

KM 提取结果

2 个 Figure · 4 个 KM 面板

进入结果中心
KM Figure2 个面板

Fig. 5

Exploratory analysis of EFS by pCR status. Analysis of EFS according to pCR status at an individual patient level by treatment group.

pCR_subgroup

EFS

Fig. 5 · Panel pCR_subgroup

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel pCR_subgroup 是同一 Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线 2:extreme upward reversal
查看结果
Non-pCR_subgroup

EFS

Fig. 5 · Panel Non-pCR_subgroup

failed 待 EXE 对齐 预期 2 条 已提取 0 条

Panel Non-pCR_subgroup 是同一 Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 2 条,实际恢复 0 条
No curves extracted
查看结果
KM Figure2 个面板

Extended Data Fig. 5

Outcomes according to post-surgery ctDNA status. a ) DFS. b ) OS. Vertical bars represent censoring.

A

DFS

Extended Data Fig. 5 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Extended Data Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

OS

Extended Data Fig. 5 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Extended Data Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(8,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Patient disposition. Flowchart showing patient disposition and sample availability. ddAC, dose-dense doxorubicin and cyclophosphamide; CT, chemotherapy.
非 KM Figure
Fig. 2EFS, DFS and OS. a , EFS in the ITT population. b , EFS subgroup analysis ( n , number of individual patients in each subgroup; dashed line, HR in the ITT population; one patient with stage IV disease not included in subgroup analyses by stage). c , DFS in the ITT population. d , OS in the ITT population. IC, immune cells.
非 KM Figure
Fig. 3Exploratory analysis of ctDNA and pCR. a , Prevalence of ctDNA-positive status over time. b , ctDNA levels over time according to pCR status; shaded area, s.e. c , ctDNA levels in individual patients over time. d , Relationships between ctDNA clearance at surgery, treatment group and pCR status ( n , number of individual patients in each subgroup; vertical bars, Clopper–Pearson 95% CIs). a Pooled treatment groups.
非 KM Figure
Fig. 4Exploratory analysis of outcomes according to presence/absence of ctDNA at surgery (ctDNA-evaluable population with ctDNA-positive status at baseline and ctDNA-evaluable at the time of surgery). a , DFS and OS by ctDNA clearance at surgery (pooled treatment groups). b , DFS and OS by pCR and ctDNA at surgery (pooled treatment groups). Vertical bars, censoring.
非 KM Figure
Extended Data Fig. 1Mean change from baseline over time for patient-reported outcomes. a , Physical functioning. b , Role functioning. c , HRQoL. Error bars depict 95% CIs. BL, baseline; C, cycle; GHS, Global Health Status; HRQoL, health-related quality of life; M, month; TxDC, treatment discontinuation.
非 KM Figure
Extended Data Fig. 2Patient-reported treatment bother, FACT-G GP5 item ‘I am bothered by side effects of treatment’. Proportion of patients selecting each response option of the FACT-G GP5 item by visit in the atezolizumab-chemotherapy and chemotherapy-alone groups. FACT-G, Functional Assessment of Cancer Therapy – General.
非 KM Figure
Extended Data Fig. 3DFS and OS according to. a , ctDNA cleared versus not cleared at week 7. b , ctDNA cleared versus not cleared at week 7 according to pCR status. c , ctDNA status (always positive ( n = 11) versus negative for at least one timepoint ( n = 119)).
非 KM Figure
Extended Data Fig. 4Treatment outcomes in patients without pCR or ctDNA clearance. Exploratory analysis of DFS and OS by treatment group in non-pCR patients with positive ctDNA status at surgery. Vertical bars represent censoring.
非 KM Figure